safety

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…

3 weeks ago

MemeCore KBW 2025 Side Event “HALLOMEME: Ride Until Next Morning” Concludes with Great Success

SEOUL, South Korea, Sept. 26, 2025 /PRNewswire/ -- MemeCore, the first Layer 1 blockchain built for Meme 2.0, successfully concluded…

3 weeks ago

BYD improves Assisted Driving system in response to Euro NCAPs ATTO 3 grading

LEUVEN, BELGIUM – BYD has responded to the ’Not Recommended’ grading which Euro NCAP gave to the ATTO 3’s Assisted…

3 weeks ago

ADVANCION PUBLISHES 2024 CORPORATE SUSTAINABILITY REPORT

Fourth annual report highlights continued progress in sustainable innovation, safety, and responsible resource stewardship BUFFALO GROVE, Ill., Sept. 24, 2025…

3 weeks ago

Spotlight on Chery International User Summit: LEPAS to Fully Unlock Value and Invite Global Users on a Journey of Elegant Co-Creation

WUHU, China, Sept. 24, 2025 /PRNewswire/ -- From October 17–21, 2025, the Chery International User Summit, themed "CO-CREATE•CO-DEFINE", will debut as…

3 weeks ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

4 weeks ago

Japan Ground Self-Defense Force Adopts MEDIROM MOTHER Labs REMONY for Advanced Health Monitoring and Heatstroke Safety

TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM…

4 weeks ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

4 weeks ago

izmomicro Announces Breakthrough in High-Power Motor Control Technology

BANGALORE, India, Sept. 16, 2025 /PRNewswire/ -- izmomicro (www.izmomicro.com), a division of izmo Ltd., today announced a major breakthrough in high-performance…

1 month ago

Clinically Proven Human Milk Probiotic LC40 supports Infant Health and Breastfeeding Mothers

SINGAPORE, Sept. 15, 2025 /PRNewswire/ -- Supported by six clinical studies and two safety trials, Kerry's LC40® is the first probiotic…

1 month ago